Pathogenic variants in the BRCA1/2 genes are associated with a 55%–72% lifetime risk for breast cancer (BC), 26%–83% for contralateral BC, and 17–59% for ovarian cancer.1, 2. This evidence concerns the gene BRCA1 and breast cancer.